MAM
RXRX icon

Martingale Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Martingale Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,313
Closed -$252K – 842
2024
Q1 		$252K Sell
25,313
-400
-2% -$4.45K 0.01% 732
2023
Q4 		$254K Buy
25,713
+600
+2% +$4.28K 0.01% 724
2023
Q3 		$192K Sell
25,113
-89
-0.4% -$888 ﹤0.01% 752
2023
Q2 		$188K Sell
25,202
-198
-0.8% -$1.39K ﹤0.01% 771
2023
Q1 		$169K Buy
25,400
+200
+0.8% +$1.59K ﹤0.01% 791
2022
Q4 		$194K Hold
25,200
– – ﹤0.01% 794
2022
Q3 		$269K Buy
25,200
+14,100
+127% +$143K 0.01% 728
2022
Q2 		$91K Buy
+11,100
New +$74.3K ﹤0.01% 830

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Martingale Asset Management's RXRX Position: Q2 2024 in Review

Martingale Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2024, closing a stake of 25,313 shares — an estimated $252K sold.

Martingale Asset Management first reported a position in RXRX in Q2 2022 and held it in 8 quarters. The position peaked at $269K in Q3 2022. 270 funds tracked by Wall St. Rank hold RXRX as of Q2 2024.

  • Martingale Asset Management reported no remaining Recursion Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Martingale Asset Management sold 25,313 Recursion Pharmaceuticals shares in Q2 2024, an estimated $252K.
  • Martingale Asset Management first reported a position in Recursion Pharmaceuticals in Q2 2022 and held it in 8 quarters.
  • Martingale Asset Management's Recursion Pharmaceuticals position peaked at $269K in Q3 2022.
  • 270 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2024.

Based on Martingale Asset Management's 13F filing for Q2 2024, filed 12 Aug 2024.